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Objectives
The aim of the study was to evaluate the efficacy of dual therapy with lamivudine (3TC), with dose
adjustment for renal function, and dolutegravir (DTG) in a subgroup of patients fully suppressed
on treatment who were switched because of concerns about comorbidity and toxicity on their
current triple drug regimen.
Methods
A retrospective evaluation of clinical and pathological parameters from an electronic patient
record from a single centre was carried out.
Results
There were no virological failures in 52 patients with a median age of 60.5 years. The median
duration of follow-on dual therapy was 2.29 years (28 months; range 1.10–3.34 years). In 25 of 52
(48%) cases, the dose of 3TC was adjusted taking into account reduced renal function, and none of
these patients experienced virological failure. Four additional patients discontinued early, because
of side effects of the switch, with no failure.
Conclusions
This retrospective review suggests that 3TC and DTG may be effective in controlling viral load in
older patients with comorbidities. This regimen appears to be a useful option in the context of
comorbidities (including renal impairment) and polypharmacy in older patients. However, this
review has been conducted in one centre and in a small population of patients. Therefore, further
multicentre trials involving larger populations of patients are needed.
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Introduction
The life expectancy of people living with HIV has
improved dramatically with the advent of effective ther-
apy and an increasing proportion of people are aged 50
years or older. The requirement for lifelong therapy and
the management of non-HIV-related comorbidities has
become increasingly important as patients are living well
with HIV. As a result, there is more interest in simplified
antiretroviral therapies (ARTs) that are efficacious, well
tolerated, and free from drug interactions.
Dual therapy as maintenance is an approach that is
being evaluated as a means of reducing potential side
effects and increasing tolerability by reducing the number
of agents, as well as reducing drug–drug interactions. Data
have been reported on the use of dolutegravir (DTG) com-
bined with rilpivirine (RPV) [1] and lamivudine (3TC) [2].
The analysis of 48-week data from the GEMINI 1 and 2
studies, investigated DTG and 3TC in ART-na€ıve patients,
demonstrated noninferiority of this regimen when com-
pared with DTG and tenofovir disoproxil fumarate (TDF)/
emtricitabine (FTC). Good tolerability was also demon-
strated.
The aim of this review was to assess the efficacy, dura-
bility and tolerability of simplifying to once a day (OD)
therapy with DTG and 3TC in a real-life cohort of
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patients on fully suppressive ART and switched for the
purposes of simplification or because of toxicities or
comorbidities. This cohort is of interest as 3TC was used
in an adjusted dose according to renal function, and this
cohort included individuals who may have been deemed
ineligible for prospective clinical trials.
Methods
This was a retrospective survey of electronic records of
patients receiving DTG and 3TC conducted in a single
urban UK centre with an HIV-infected cohort of approxi-
mately 1100 patients.
Patients were switched to dual therapy for a comorbid-
ity, drug interaction or side effect from their baseline
ART (Table 1). A proportion were selected for DTG and
renally adjusted 3TC, where there were concerns regard-
ing renal function [based on estimate glomerular filtra-
tion rate (eGFR)] as measured by CKD-Epi (Chronic
Kidney Disease – Epidemiology collaboration equation)
(mL/min/1.73 m2), i.e. eGFR was < 50 mL/min/1.73 m2.
This treatment was initiated prior to the general availabil-
ity of tenofovir alfenamide (TAF) at this centre.
Data that were collected included age and gender;
presence of concomitant disease and side effects of previ-
ous ART regimens such as abnormal laboratory test
results, adverse events and presence of drug interactions;
the duration and choice of ART at baseline and earliest
date of viral failure (i.e. two or more consecutive viral
loads > 40 HIV-1 RNA copies/mL prior to and after start-
ing dual therapy); date started ART and most recent CD4
count. The pre switch eGFR readings were taken between
2 and 6 months prior to the visit the switch occurred,
and post switch eGFR readings are most recent reading.
Patients with an eGFR > 90 mL/min/1.73 m2 were
recorded as having an eGFR of 90 mL/min/1.73 m2.
Results
Between 2015 and 2019, 56 patients switched to dual
therapy consisting of DTG 50 mg OD and 3TC. The full
dose of 3TC was 300 mg, and the renally adjusted doses
were 150 and 50 mg. Patient demographic data in
Table 2 show that the median age was 60.5 years, and
the median time on previous ART was 9.4 years, with a
range of 0.80–26.1 years. There were no viral failures in
these patients.
Of 56 patients switched, four patients discontinued
dual therapy for side effects; they had a follow-up time
of < 1 year and were on dual therapy for a median of
2 months before discontinuing. One of the four was on a
renally adjusted dose of 3TC. These four patients experi-
enced known side effects of DTG. Two patients experi-
enced severe headaches, one insomnia and the other
vivid dreams, disturbed sleep, muscle pain and bloating.
Table 1 Reasons for drug switch and prior ART therapy
Reasons for drug switch to dual therapy
eGFR 12
Proteinuria 3
Tolerability/side effects 8
Cardiovascular risk 6
Interactions 11
Hyperlipidaemia 24
Simplification/pill burden 4
No information available 1
Lamivudine dose adjustment [n (%)]
300 mg 27 (52)
150 mg 24 (46)
50 mg 1 (2)
Previous ART prior to switch
ART Number of patients
Tenofovir disoproxil fumarate 36
Abacavir 35
Zidovudine 19
Efavirenz 27
Nevirapine 10
Rilpivirine 10
Integrase inhibitors
Raltegravir 17
Dolutegravir 6
Elvitegravir 0
Boosted regimens
Atazanavir with ritonavir 16
Darunavir with ritonavir 25
Lopinavir with ritonavir 5
ART, antiretroviral therapy; eGFR, estimated glomerular filtration rate.
Table 2 Baseline demographics and patient characteristics of 52
patients
Gender [n/total (%)]
Male 44/52 (85)
Female 8/52 (15)
Age (at switch) [n/total (%)]
< 30 years 0
30–< 40 years 1
40–< 50 years 9
50–< 60 years 17
60–< 70 years 13
≥70 years 12
CD4 count (most recent, at time of data collection) [n/total (%)]
< 200 cells/lL 0
200–350 cells/lL 3
> 350 cells/lL 49
Not available 0
HIV risk acquisition [n/total (%)]
Heterosexual 24 (46)
Homosexual 26 (50)
Injecting drug use 0 (0)
Other 2 (4)
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The data for these four patients were therefore not
included.
The other 52 patients had a follow-up period of > 1 year,
and 25 of these patients were on a renally adjusted dose of
3TC. The median duration on dual therapy was 2.29 years
(28 months; range 1.10–3.34 years); the most recent med-
ian CD4 count after switch was 737 cells/lL and there were
no recorded viral failures. The median number of viral load
measurements after starting dual therapy was 6. None of
the 52 patients who continued (after 3 months) experi-
enced side effects sufficient to merit a switch.
Overall, the median eGFR of the 52 patients before
starting dual therapy was 62 mL/min/1.73 m2, and the
median of the most recent eGFR while on dual therapy
was 61 mL/min/1.73 m2. There were two patients who
did not have any recorded eGFR within 6 months of
starting dual therapy; therefore, they were not included
in the median eGFR measurement. There were five
patients who had an initial eGFR reading of > 50 mL/
min/1.73 m2 that fell below 50 mL/min/1.73 m2 while on
dual therapy, and the mean difference between measure-
ments was 7.2 mL/min/1.73 m2. Two of the five were put
on renally adjusted 3TC. There was no significant change
in mean unfasted cholesterol before (5.65 mmol/L) and
after (5.16 mmol/L) dual therapy.
However, cholesterol would not be an accurate measure
as these are unfasted retrospect readings, and factors such
as being on a protease inhibitor and/or TDF previously
may influence cholesterol levels.
For the 25 patients on renally adjusted 3TC, the median
eGFR before starting dual therapy was 47 mL/min/
1.73 m2, and while on dual therapy, the median eGFR
was 54 mL/min/1.73 m2.
There was one patient on a smaller dose of 50 mg 3TC for
1.13 years, because the patient’s initial eGFR before start-
ing on dual therapy was 20 mL/min/1.73 m2. After starting
dual therapy, eGFR improved to 44 mL/min/1.73 m2.
For the remaining 26 patients on full-dose 3TC, the
median eGFR before starting dual therapy was 62 mL/
min/1.73 m2, and after starting dual therapy, the median
was 61 mL/min/1.73 m2.
There was one viral blip (for full-dose 3TC), with full
subsequent suppression, and one death, which was not
HIV related.
Additional data on eGFR are presented in Table 3 to
show the effects of treatment change on eGFR (starting
DTG/stopping TDF).
Discussion
This retrospective case-note review provides further evi-
dence that DTG and 3TC could be a robust regimen in a
real-life clinical setting, as there was no evidence of viro-
logical failure in this case series with a median treatment
duration of 2.5 years.
The GEMINI 1 and 2 trials [3] recruited 1441 patients,
who were ART na€ıve, randomized to treatment with
either dual therapy (3TC and DTG) or triple therapy (TDF,
FTC and DTG).
The mean age was 32.5 years, with only 9% and 11%
(in respective arms) aged > 50 years. Therefore, the other-
wise excellent GEMINI trial does not include a high pro-
portion of older, treatment-experienced patients who
arguably have most to gain from treatment simplification
with a two-drug regimen. Patients with existing comor-
bidities might be taking other medication and would
probably benefit from a regimen including DTG in order
to minimize potential drug–drug interactions.
In common with data from other interventional trials,
the GEMINI trial data may not represent current popula-
tions of people receiving care for HIV infection, with the
median age of people receiving care for HIV infection in
the UK increasing from 40 years in 2008 to 46 years in
2017. In 2017, more than a third of people receiving HIV
care in the UK were aged > 50 years [4] (2018 Report).
Similarly, the EUROSIDA HIV-infected cohort has also
seen an increase in age to a median of 48.6 years in
2014 and an increase in comorbidities [5].
A multicentre study in Italy by Borghetti et al. [2]
looked at 206 patients stable on combination ART (cART)
with a median age of 51 years who were switched to 3TC
and DTG primarily for simplification (31%) or toxicity
Table 3 Effects of treatment change on estimated glomerular filtration rate (eGFR)
Drugs
Median eGFR before dual therapy (mL/
min/1.73 m2)
Median eGFR after dual therapy (mL/
min/1.73 m2)
All patients (including those with previous ART containing DTG) (n = 52) 54 54
Patients without previous ART containing DTG (n = 46) 64 60
All patients (including those with previous ART containing TDF) (n = 52) 54 54
Patients without previous ART containing TDF (n = 16) 63 62
The pre switch eGFR readings were taken between 2 and 6 months prior to the visit the switch occurred, and post switch eGFR readings are most
recent reading.
ART, antiretroviral therapy; DTG, dolutegravir; TDF, tenofovir disoproxil fumarate.
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(54.4%). This is the largest cohort to date and the study
similarly reported no virological failures, an absence of
toxicity and improvements in CD4 count, CD4:CD8 ratio,
lipid profile and eGFR. In this cohort, the median age
was 51 years and it was much more representative of
people receiving care for HIV infection in Europe. The
renal dose adjustment for 3TC was not noted.
We acknowledge the limitations of these data, which
were retrospective and included patients with a range of
comorbidities and toxicity issues. However, this is the
first data series that suggests that a dose adjustment of
3TC for reduced renal function does not appear to affect
the virological outcome, albeit for a limited sample size.
These data add value to existing evidence. Our cohort
were older, with an average age of 60.5 years compared
to 32.5 years (GEMINI 1 and 2) [3], 48.6 years (EURO-
SIDA HIV) [5] and 51 years (Borghetti et al. [2]). Our
cohort were medically complex with additional diagnoses
of diabetes, hyperlipidaemia, and declining renal func-
tion, similar to the EUROSIDA HIV [5] and Borghetti
et al. [2] case series. Lastly, our cohort had a longer dura-
tion of treatment than previously reported series, of
28 months (112 weeks) compared to 48 weeks (GEMINI 1
and 2) [3] and 96 weeks (Borghetti et al. [2]).
This combination could provide an alternative, in some
patients, to switching to TAF.
Questions remain as to the long-term safety of such a
regimen and its efficacy at privileged sites, such the cen-
tral nervous system, and this treatment regimen requires
further investigation and long-term follow-up.
Conclusions
This case series suggests that switching to dual therapy
with 3TC and DTG is well tolerated, durable and
efficacious in this population with a median age of
60.5 years in a real-life clinical setting, even on a renally
adjusted 3TC dose.
This dual therapy could be considered as a promising
potential alternative where there are specific medical
needs; to avoid interactions, toxicities and effects of
comorbidities in an ageing HIV-infected cohort, espe-
cially as patients could stand to benefit from treatment
simplification. Further research is needed.
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